ENANTA PHARMACEUTICALS INC ENTA

Rank #2015 · Nasdaq · $0.3B market cap

Audited by PricewaterhouseCoopers LLP, no going-concern flag in the latest filing.

Score

36.3

P/E

-2.3

P/B

0.97

ROE

-41.6%

Op. Margin

-173.2%

Debt Ratio

77%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆

Average

P/E -2.3x, P/B 0.97x. Ranks in the top 54% of the universe.

Profitability ★☆☆☆☆

Poor

ROE -41.6%. Ranks in the top 90% of the universe.

Safety ★★★☆☆

Good

Debt ratio 77%. Ranks in the top 32% of the universe.

Growth ★☆☆☆☆

Poor

Revenue decline of 8.1% year over year. Ranks in the top 81% of the universe.

Safety is the relative strength · Profitability is the relative weakness (relative to this universe).

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2013	$0.0B	$0.0B	$0.0B	$-0.2B	60.4	-5
2014	$0.0B	$0.0B	$0.0B	$-0.1B	51.0	-5
2015	$0.0B	$0.0B	$0.0B	$-0.1B	28.2	-6
2016	$0.0B	$0.0B	$0.0B	$0.1B	39.8	9
2017	$0.2B	$0.1B	$0.1B	$0.1B	77.2	8
2018	$0.1B	$0.0B	$0.0B	$0.2B	34.9	11
2019	$0.1B	$0.0B	$0.0B	$0.3B	23.9	8
2020	$0.2B	$0.1B	$0.1B	$0.3B	42.7	9
2021	$0.2B	$0.0B	$0.0B	$0.4B	17.9	8
2022	$0.1B	$-0.0B	$-0.0B	$0.5B	-34.0	9
2023	$0.1B	$-0.1B	$-0.1B	$0.5B	-112.9	12
2024	$0.1B	$-0.1B	$-0.1B	$0.4B	-143.7	61
2025	$0.1B	$-0.1B	$-0.1B	$0.3B	-173.2	77